CNMD Conmed

CONMED Corp. operates as a medical technology company, which engages in the development, manufacture and sale of surgical devices and related equipment. It operates through the following geographical segments: United States; Americas excluding the United States; Europe, Middle East, and Africa; and Asia Pacific. Its product lines also include orthopedic surgey and general surgery. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Utica, NY.
Company profile
Ticker
CNMD
Exchange
Website
CEO
Curt Hartman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Natus Medical • Masimo • LivaNova • Outset Medical • Fonar • Cutera • Inmode • Stereotaxis ...
SEC CIK
Corporate docs
IRS number
160977505
CNMD stock data
()
Press releases
CONMED Corporation to Announce First Quarter 2021 Financial Results on April 28, 2021
1 Apr 21
CONMED Corporation Announces Annual Meeting of Stockholders
23 Mar 21
CONMED Corporation to Participate in a Virtual Fireside Chat at the KeyBanc Life Sciences & MedTech Investor Forum
15 Mar 21
CONMED Corporation Announces Quarterly Cash Dividend
23 Feb 21
CONMED Corporation to Participate in a Virtual Fireside Chat at the SVB Leerink Global Healthcare Conference
16 Feb 21
Calendar
22 Feb 21
17 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from Conmed earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 27.36M | 27.36M | 27.36M | 27.36M | 27.36M | 27.36M |
Cash burn (monthly) | 2.75M | (positive/no burn) | (positive/no burn) | (positive/no burn) | (positive/no burn) | (positive/no burn) |
Cash used (since last report) | 9.82M | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 17.54M | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 6.4 | n/a | n/a | n/a | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 21 | Heather L Cohen | Common Stock | Grant | Aquire A | No | No | 124.06 | 191 | 23.7K | 24,456 |
31 Mar 21 | Daniel Jonas | Common Stock | Grant | Aquire A | No | No | 124.06 | 43 | 5.33K | 13,806 |
31 Mar 21 | Todd W. Garner | Common Stock | Grant | Aquire A | No | No | 124.06 | 191 | 23.7K | 6,201 |
1 Mar 21 | Terence M Berge | Common Stock | Sell | Dispose S | No | No | 122.5 | 2,550 | 312.38K | 1,004 |
1 Mar 21 | Terence M Berge | Common Stock | Option exercise | Aquire M | No | No | 97.69 | 2,550 | 249.11K | 3,554 |
1 Mar 21 | Terence M Berge | Common Stock | Sell | Dispose S | No | No | 122.5 | 5,400 | 661.5K | 1,004 |
1 Mar 21 | Terence M Berge | Common Stock | Option exercise | Aquire M | No | No | 78.76 | 5,400 | 425.3K | 6,404 |
1 Mar 21 | Terence M Berge | Common Stock | Sell | Dispose S | No | No | 122.5 | 2,700 | 330.75K | 1,004 |
1 Mar 21 | Terence M Berge | Common Stock | Option exercise | Aquire M | No | No | 59.96 | 2,700 | 161.89K | 3,704 |
1 Mar 21 | Terence M Berge | Common Stock | Sell | Dispose S | No | No | 122.5267 | 2,800 | 343.07K | 1,004 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
---|---|
Total holders | 246 |
Opened positions | 40 |
Closed positions | 33 |
Increased positions | 94 |
Reduced positions | 76 |
13F shares |
Current |
---|---|
Total value | 3.45B |
Total shares | 30.82M |
Total puts | 84.7K |
Total calls | 27.8K |
Total put/call ratio | 3.0 |
Largest owners |
Shares | Value |
---|---|---|
BLK Blackrock | 4.48M | $501.52M |
Vanguard | 3M | $336.27M |
Champlain Investment Partners | 1.69M | $189.51M |
Earnest Partners | 1.58M | $176.44M |
STT State Street | 972.44K | $109.1M |
Dimensional Fund Advisors | 963.73K | $107.94M |
IVZ Invesco | 930.26K | $104.19M |
PFG Principal Financial Group Inc - Registered Shares | 916.93K | $102.7M |
MCQEF Macquarie | 775.72K | $86.88M |
Capital Research Global Investors | 718.3K | $80.45M |
Financial report summary
?Risks
- Our financial performance is dependent on conditions in the healthcare industry and the broader economy.
- The COVID-19 global pandemic may pose significant risks to our business if the pandemic, and various government responses to it, continue for an extended period of time.
- As a manufacturer of medical devices that interacts with physicians and health care providers domestically and internationally, we face risks under domestic and foreign regulations, including the Foreign Corrupt Practices Act.
- The highly competitive market for our products may create adverse pricing pressures.
- Cost reduction efforts in the healthcare industry could put pressures on our prices and margins.
- We may not be able to keep pace with technological change or to successfully develop new products with wide market acceptance, which could cause us to lose business to competitors.
- Our variable rate indebtedness subjects us to interest rate risk, which could cause our debt service obligations to increase significantly.
- Our interest rates may be impacted by the phase out of LIBOR.
- The convertible notes hedge and warrant transactions that we entered into in connection with the offering of the Convertible Notes may affect the value of the Convertible Notes and our common stock.
- We are subject to counterparty risk with respect to the convertible notes hedge transactions.
- The terms of any future preferred equity or debt financing may give holders of any preferred securities or debt securities rights that are senior to rights of our common shareholders or impose more stringent operating restrictions on our company.
- We could experience a failure of a key information technology system, process or site or a breach of information security, including a cybersecurity breach or failure of one or more key information technology systems, networks, processes, associated sites or service providers, and could potentially become liable for a breach of various data privacy regulations.
- We rely on a third party to obtain, process and distribute sports medicine allograft tissue. If such tissue cannot be obtained, is not accepted by the market or is not accepted under numerous government regulations, our results of operations could be negatively impacted.
- We distribute some products for third-party companies, and cannot ensure that our rights to distribute such third-party products will continue indefinitely.
- If we lose our patents or they are held to be invalid, or if our products or services infringe on third party patents, we could become subject to liability and our competitive position could be harmed.
- Damage to our physical properties as a result of windstorm, earthquake, fire or other natural or man-made disaster may cause a financial loss and a loss of customers.
- Our new products may fail to achieve expected levels of market acceptance.
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
abnormally, accuracy, Addison, Additionally, administered, aging, agreed, Aid, ambulatory, Anchor, Anthrex, autoclavable, belief, bench, borne, broadest, broadly, California, cleaning, closure, conserved, COVID, culture, cutting, deferral, depressed, depression, desired, discovered, discreet, distancing, duration, EEG, EU, exculpation, faster, floor, footnote, formal, forum, governmental, grid, half, heightened, hygiene, ICO, imperative, importantly, Incheon, intentionally, job, light, maximum, MDD, MDR, methodology, MicroFree, moving, NYSE, pandemic, passed, people, population, postponed, prolonged, proper, question, rationalization, rebound, rebounding, recapitalization, recession, recruiting, recruitment, remotely, residual, resurgence, rounded, Seoul, sequential, show, slightly, social, South, spread, stimulate, stricter, subsided, surveillance, taxpayer, threatened, TitanTM, track, tracking, trademark, travel, tuition, turnover, uncertain, undertaken, underutilization, visibility, voluntary, wake, weakened, winding, written
Removed:
anticipating, application, arthroplasty, arthroscopy, chairman, compensatory, eligible, enactment, excise, expensing, Headquartered, imposed, impossible, limitation, Luke, modularity, mortgage, Nemo, neurosurgery, onsite, pacing, Pomilio, preliminary, Prime, punitive, repeal, room, simplify, stoppage, SurgiQuest, transparency, trauma, unvested, verdict, versatility
Financial reports
10-K
2020 FY
Annual report
22 Feb 21
10-Q
2020 Q3
Quarterly report
29 Oct 20
10-Q
2020 Q2
Quarterly report
30 Jul 20
10-Q
2020 Q1
Quarterly report
30 Apr 20
10-K
2019 FY
Annual report
24 Feb 20
10-Q
2019 Q3
Quarterly report
31 Oct 19
10-Q
2019 Q2
Quarterly report
1 Aug 19
10-Q
2019 Q1
Quarterly report
26 Apr 19
10-K
2018 FY
Annual report
25 Feb 19
10-Q
2018 Q3
Quarterly report
2 Nov 18
Current reports
8-K
Other Events
23 Feb 21
8-K
CONMED Corporation Announces Fourth Quarter and Full-Year 2020 Financial Results
27 Jan 21
8-K
Entry into a Material Definitive Agreement
23 Nov 20
8-K
Other Events
13 Nov 20
8-K
CONMED Corporation Announces Third Quarter 2020 Financial Results
28 Oct 20
8-K
Departure of Directors or Certain Officers
1 Oct 20
8-K
Other Events
14 Aug 20
8-K
CONMED Corporation Announces Second Quarter 2020 Financial Results
29 Jul 20
8-K
Entry into a Material Definitive Agreement
22 May 20
8-K
CONMED Corporation Announces First Quarter 2020 Financial Results
29 Apr 20
Registration and prospectus
25-NSE
Exchange delisting
26 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
22 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
22 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
22 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
22 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
22 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
22 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
22 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
22 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
22 May 20
Proxies
DEFA14A
Additional proxy soliciting materials
9 Apr 21
DEF 14A
Definitive proxy
9 Apr 21
DEFA14A
Additional proxy soliciting materials
11 May 20
DEF 14A
Definitive proxy
10 Apr 20
PRE 14A
Preliminary proxy
16 Mar 20
DEF 14A
Definitive proxy
12 Apr 19
DEF 14A
Definitive proxy
11 Apr 18
DEF 14A
Definitive proxy
12 Apr 17
DEF 14A
Definitive proxy
14 Apr 16
DEF 14A
Definitive proxy
16 Apr 15
Other
SD
Conflict minerals disclosure
27 May 20
SD
Conflict minerals disclosure
29 May 19
UPLOAD
Letter from SEC
28 Oct 18
CORRESP
Correspondence with SEC
17 Oct 18
SD
Conflict minerals disclosure
30 May 18
SD
Conflict minerals disclosure
23 May 17
SD
Conflict minerals disclosure
24 May 16
SD
Conflict minerals disclosure
27 May 15
UPLOAD
Letter from SEC
22 Sep 14
CORRESP
Correspondence with SEC
11 Sep 14
Ownership
4
CONMED / Todd W Garner ownership change
2 Apr 21
4
CONMED / Daniel S Jonas ownership change
2 Apr 21
4
CONMED / Heather L Cohen ownership change
2 Apr 21
4
CONMED / JOHN JED KENNEDY ownership change
3 Mar 21
4
CONMED / PETER K SHAGORY ownership change
3 Mar 21
4
CONMED / Stanley W Peters III ownership change
3 Mar 21
4
CONMED / Johonna Marie Pelletier ownership change
3 Mar 21
4
CONMED / DANIEL JONAS ownership change
3 Mar 21
4
CONMED / Curt R Hartman ownership change
3 Mar 21
4
CONMED / Todd W. Garner ownership change
3 Mar 21
Patents
APP
Utility
Sheathed Surgical Saw Blade with Bearings
8 Apr 21
A sheathed blade assembly for minimizing or preventing contact between the moving interior blade and the exterior sheath.
GRANT
Utility
Single lumen gas sealed trocar for maintaining stable cavity pressure without allowing instrument access therethrough during endoscopic surgical procedures
6 Apr 21
A system for performing an endoscopic surgical procedure in a surgical cavity of a patient that includes a multi-lumen tube set including a dual lumen portion having a pressurized gas line and a return gas line for facilitating gas recirculation relative to the surgical cavity of the patient, and a single lumen portion having a gas supply and sensing line for delivering insufflation gas to the surgical cavity of the patient and for periodically sensing pressure within the surgical cavity of the patient, a first gas sealed single lumen access port communicating with the dual lumen portion of the tube set and a second valve sealed single lumen access port communicating with the single lumen portion of the tube set.
APP
Utility
Endoscopic Visualization System
1 Apr 21
An endoscopic visualization system (10) includes an endoscopic subsystem (26) comprising an endoscope having an optical channel and an illumination channel, an image sensor operatively coupled to receive light from the optical channel and a solid-state light source operatively coupled to transmit light through the illumination channel; at least one electrical cable extending from the endoscopic subsystem; and a monitor subsystem (12) comprising a frame defining an inner compartment, a display screen and at least one port configured to receive the at least one electrical cable connected to the endoscopic subsystem.
GRANT
Utility
System and method for securing tissue to bone
30 Mar 21
Disclosed herein are methods and devices for securing soft tissue to a rigid material such as bone.
APP
Utility
Cannulated Tissue Needle with Suture Grasping Mechanism
25 Mar 21
A suture passer for use in arthroscopic soft tissue repair procedures.
Transcripts
2020 Q4
Earnings call transcript
28 Jan 21
2020 Q3
Earnings call transcript
28 Oct 20
2020 Q2
Earnings call transcript
29 Jul 20
2020 Q1
Earnings call transcript
29 Apr 20
2019 Q4
Earnings call transcript
29 Jan 20
2019 Q3
Earnings call transcript
30 Oct 19
2019 Q2
Earnings call transcript
31 Jul 19
2019 Q1
Earnings call transcript
24 Apr 19
2018 Q4
Earnings call transcript
22 Jan 19
2018 Q3
Earnings call transcript
2 Nov 18